GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » IntelliPharmaCeutics International Inc (TSXV:IPCI) » Definitions » E10

IntelliPharmaCeutics International (TSXV:IPCI) E10 : C$-2.73 (As of Aug. 2023)


View and export this data going back to 1999. Start your Free Trial

What is IntelliPharmaCeutics International E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

IntelliPharmaCeutics International's adjusted earnings per share data for the three months ended in Aug. 2023 was C$-0.081. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is C$-2.73 for the trailing ten years ended in Aug. 2023.

During the past 3 years, the average E10 Growth Rate was 9.80% per year. During the past 5 years, the average E10 Growth Rate was 8.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of IntelliPharmaCeutics International was 12.30% per year. The lowest was -58.50% per year. And the median was -3.20% per year.

As of today (2024-05-21), IntelliPharmaCeutics International's current stock price is C$0.08. IntelliPharmaCeutics International's E10 for the quarter that ended in Aug. 2023 was C$-2.73. IntelliPharmaCeutics International's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of IntelliPharmaCeutics International was 17.37. The lowest was 0.56. And the median was 1.74.


IntelliPharmaCeutics International E10 Historical Data

The historical data trend for IntelliPharmaCeutics International's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IntelliPharmaCeutics International E10 Chart

IntelliPharmaCeutics International Annual Data
Trend Nov13 Nov14 Nov15 Nov16 Nov17 Nov18 Nov19 Nov20 Nov21 Nov22
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -4.27 -4.06 -3.47 -3.20 -2.98

IntelliPharmaCeutics International Quarterly Data
Nov18 Feb19 May19 Aug19 Nov19 Feb20 May20 Aug20 Nov20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.05 -2.98 -2.90 -2.83 -2.73

Competitive Comparison of IntelliPharmaCeutics International's E10

For the Biotechnology subindustry, IntelliPharmaCeutics International's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IntelliPharmaCeutics International's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IntelliPharmaCeutics International's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where IntelliPharmaCeutics International's Shiller PE Ratio falls into.



IntelliPharmaCeutics International E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, IntelliPharmaCeutics International's adjusted earnings per share data for the three months ended in Aug. 2023 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Aug. 2023 (Change)*Current CPI (Aug. 2023)
=-0.081/125.3885*125.3885
=-0.081

Current CPI (Aug. 2023) = 125.3885.

IntelliPharmaCeutics International Quarterly Data

per share eps CPI Adj_EPS
201311 -3.251 97.182 -4.195
201402 0.995 98.051 1.272
201405 -1.525 99.394 -1.924
201408 -0.765 99.315 -0.966
201411 -0.680 99.078 -0.861
201502 -0.500 99.078 -0.633
201505 -0.731 100.263 -0.914
201508 -1.052 100.579 -1.311
201511 -1.726 100.421 -2.155
201602 -1.242 100.421 -1.551
201605 -1.036 101.765 -1.276
201608 -0.910 101.686 -1.122
201611 -1.881 101.607 -2.321
201702 -0.918 102.476 -1.123
201705 -0.816 103.108 -0.992
201708 -1.046 103.108 -1.272
201711 -0.984 103.740 -1.189
201802 -1.146 104.688 -1.373
201805 -0.090 105.399 -0.107
201808 -1.187 106.031 -1.404
201811 -0.528 105.478 -0.628
201902 -0.211 106.268 -0.249
201905 -0.135 107.927 -0.157
201908 -0.093 108.085 -0.108
201911 -0.066 107.769 -0.077
202002 -0.106 108.559 -0.122
202005 -0.056 107.532 -0.065
202008 0.053 108.243 0.061
202011 -0.078 108.796 -0.090
202102 -0.051 109.745 -0.058
202105 -0.049 111.404 -0.055
202108 -0.050 112.668 -0.056
202111 -0.075 113.932 -0.083
202202 -0.038 115.986 -0.041
202205 -0.039 120.016 -0.041
202208 -0.013 120.569 -0.014
202211 -0.027 121.675 -0.028
202302 -0.013 122.070 -0.013
202305 -0.003 124.045 -0.003
202308 -0.081 125.389 -0.081

Add all the adjusted EPS together and divide 10 will get our e10.


IntelliPharmaCeutics International  (TSXV:IPCI) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of IntelliPharmaCeutics International was 17.37. The lowest was 0.56. And the median was 1.74.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


IntelliPharmaCeutics International E10 Related Terms

Thank you for viewing the detailed overview of IntelliPharmaCeutics International's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


IntelliPharmaCeutics International (TSXV:IPCI) Business Description

Traded in Other Exchanges
Address
30 Worcester Road, Toronto, ON, CAN, M9W 5X2
IntelliPharmaCeutics International Inc is a pharmaceutical company. The company is engaged in the research, development, and manufacturing of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its patented Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to the development of a range of existing and new pharmaceuticals. Its ongoing drug development programs are at various stages of development in therapeutic areas that include neurology, cardiovascular, GIT, and pain. The company's product, a generic of Focalin XR, is partnered with Par Pharmaceutical, Inc. and received FDA approval. It derives revenue from the United States.

IntelliPharmaCeutics International (TSXV:IPCI) Headlines

No Headlines